Achieve Life Sciences files $150.0 million at-the-market share sale program
On August 14, 2026, Achieve Life Sciences entered into an Open Market Sale Agreement with Jefferies LLC, allowing the company to sell up to $150.0 million of common stock at its sole discretion. Sales would dilute existing shareholders, and the company says proceeds will fund cytisinicline commercialization, a Phase 3 trial for e-cigarette cessation, and working capital.
Key points
- Up to $150.0 million of common stock may be sold through Jefferies as sales agent, at the company's discretion
- Jefferies may receive compensation of up to 3.0% of aggregate gross proceeds, plus reimbursement of certain expenses
- Shares are issued under a Form S-3 registration statement filed January 23, 2026, and a prospectus supplement filed August 14, 2026
- The company has no obligation to sell shares and may suspend offers at any time
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.